Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal

Stock Track

05/19

PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.

The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.

Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1148340759"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148340759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148340759?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148340759","market":"sg","top_or_hot":-1,"title":"Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal","media":"Stock Track","content":"<p>PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.</p><p>The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.</p><p>Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-19 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.</p><p>The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.</p><p>Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1148340759","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148340759","pubTimestamp":1779157296,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.The surge appears driven by the company's recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"个股追踪|PegBio盘中大涨28.96%独家GLP-1药物商业化交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}